BÜHLMANN Laboratories AG

The recently launched EntroGen BRAF (V600E/K/D) test, that can be run on your real-time PCR instrument, is now CE-IVD marked

Buhlmann — 2012-05-09T06:24:48Z

The EntroGen BRAF (V600E/K/D) test is a very useful tool for the detection of important mutations found in melanoma, because it detects, beside the V600E mutation, also the V600K and the V600D mutations. The test kit contains 64 reactions and it can be run on all real-time PCR instruments capable of detecting FAM and VIC fluorescent probes.
More information about the new EntroGen BRAF test can be found here.

INFINITI KRAS-BRAF study from the Basel Institut of Pathology published in the Diagnostic Molecular Pathology journal.

Buhlmann — 2012-03-23T16:16:50Z

New publication about the INFINITI KRAS assay in the Journal Diagn Mol Path 21/1 2012 14-23, Bihl et al. In this study from the Institute of Pathology at the University Hospital Basel, the performance of the INFINITI KRAS assay has been compared to Dideoxy- and Pyrosequencing in a comparative manner, by investigating 100 colorectal carcinoma samples with known KRAS mutation status (62 mutated cases and 38 wild type cases). Targeting the epidermal growth factor receptor (EGFR) is a new therapeutic option for patients with metastatic colorectal or lung carcinoma. However, the therapy efficiency highly depends on the KRAS mutation status in the given tumor. Therefore a reliable and secure KRAS mutation testing is crucial.

The authors conclude that the INFINITI KRAS assay seems to be slightly more sensitive compared to Dideoxy- and Pyrosequencing. In addition the hands-on time to process the samples was clearly the shortest on the INFINITI.

Recent publications on BÜHLMANN calprotectin assays

buhlmann — 2012-02-13T13:54:11Z

Three very interesting new papers have been published recently. Manz et al. describes the quality and usefulness of the BÜHLMANN calprotectin ELISA in an observational study to screen for organic vs. non-organic gut disease, which very impressively reflects the daily practice of screening unknown patients with abdominal discomfort. A real time, real life situation reflected.

Another brand new paper by Richard Fedorak in Alberta Canada, describes the use of BÜHLMANN ELISA and of Quantum Blue Rapid Test to distinguish IBD from IBS as well. The clear cut message here is that the Quantum Blue, just like the ELISA are very efficient and useful to do this job.

Finally in Clinical Biochemistry, Mirja Mindermark and Anders Larsson show the general health economic benefit of performing calprotectin assays as pre endoscopic screening, here with the BÜHLMANN ELISA. The take home message is, that by routinely performing calprotectin testing the number of endoscopies can be reduced to those really necessary ones and together with that the costs for health care providers significantly drop.

NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND

buhlmann — 2011-12-20T14:42:24Z

BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1^st 2012, has an official new position in the reimbursement list of the Swiss Ministry of Health, increasing even more the availability, and the acceptance within the laboratories and above all, for the patients and doctors, from the specialist to the General Practitioner. The position code for calprotectin analysis is: N 1224.10 and is reimbursed with 61 Swiss Francs.

This has been achieved through excellent collaborations and a hand in hand effort between the Swiss authorities, independent experts in the medical, the laboratory chemistry and immunology field, as well as BÜHLMANN Laboratories, as one driving force to increase acceptance of the most important and useful biomarker available for IBD diagnosis.

This great achievement is also a very important milestone for reimbursement efforts in countries that are still on the way to this development. BÜHLMANN is certainly going to be in the lead towards this goal worldwide.

Since 2007 BÜHLMANN is fully commited in improving the position of this invaluable diagnostic tool and is the market leader for calprotectin determinations with the monoclonal ELISA assay, as well as the rapid and quantitative Quantum Blue® Calprotectin lateral flow test.

New Seegene DPO Movie showing how this unique and proprietary technology is working to allow innovative multiplexing.

buhlmann — 2011-10-19T08:37:58Z

The unique and proprietary DPO™(Dual-Priming-Oligonucleotide) technology is the corner stone for all of the Seegene products, and it is the key to achieve a very high specificity and to enable the innovative multiplexing that we can offer with the Seegene products.

Watch the movie to learn how it is exactly working and which benefits DPO™ can bring to your lab.

New EntroGen BRAF test (V600E/K/D) for the detection of important mutations found in melanoma on your real-time PCR instrument.

buhlmann — 2011-09-22T06:50:07Z

EntroGen has a new BRAF test that detects, beside the V600E mutation, also the V600K and the V600D, which are important mutations found in melanoma.
The test kit contains 64 reactions and it can be run on all real-time PCR instruments capable of detecting FAM and VIC fluorescent probes.

More information about the new EntroGen BRAF test can be found here.

BÜHLMANN innovations and news at the JIB

buhlmann — 2011-09-12T14:19:06Z

At the JIB Congress in Paris, 8^th – 10^th November 2011, BÜHLMANN presents the MDx products of EntroGen and AutoGenomics as well as new developments of its own unique products. Read more about BÜHLMANN Innovations and News and visit us at our stand Curie D93.

BÜHLMANN now distributes EntroGen’s EGFR and KRAS/BRAF tests in Switzerland/Liechtenstein, Austria and France

buhlmann — 2011-08-24T08:45:46Z

The EGFR test kit detects 29 mutations and the KRAS-BRAF kit detects 12 mutations. EntroGen’s analysis kits require a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes. All the reagents required for the PCR amplification/detection, as well as validated reaction controls, are included in the kit.

More information about the EntroGen’s EGFR and KRAS/BRAF test can be found here.

BÜHLMANN Laboratories sets structures for its future

buhlmann — 2011-07-04T07:05:46Z

BÜHLMANN Laboratories AG announces the nomination of Dr. Thomas Hafen as CEO, starting July 1^st 2011. Roland P. Bühlmann continues to play an active role. files/documents/news/2011-06-27-buehlmann-labs-sets-structures-for-its-futre.doc.

New Product Names within the Cellular Allergy Productline

buhlmann — 2011-06-09T16:08:43Z

We are pleased to inform you that BÜHLMANN has new products names starting from June 14, 2011, for Flow2 CAST^® and CAST-2000^® as follows:

Old	New	Unchanged Ordering Code
Flow2 CAST^®	Flow CAST^®	FK-CCR
CAST^®-2000	CAST^® ELISA	EK-CAST
CAST^®-2000	CAST^® ELISA	EK-CAST5

The products, kit components, ordering codes as well as prices remain the same.

In the first period of the change it could be possible having both, new and old names, in circulation. Please don't be confused it is only a change of name, the products remain the same.